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Objective: To review a 2-institution experience with minimally invasive mitral valve surgery over a 12-year
period.
Methods:We prospectively collected data on all patients having minimally invasive mitral valve surgery through
a right minithoracotomy between May 1996 and May 2008.
Results: A total of 1178 patients included 941 (79.9%) patients having mitral valve repair and 237 (20.1%) hav-
ing mitral valve replacement. The mean age was 61.1 13.9 years, mean ejection fraction was 52.8% 12.1%,
and 221 patients (18.8%) were having reoperations. Operative mortalities for mitral valve repair and mitral valve
replacement were 2.1% and 4.6%, and for isolated primary MVP and MVR were 0.2% and 3.6%, respectively.
Repair techniques included annuloplasty (98.2%), leaflet resection (40.7%), sliding plasty (21.0%), chordal
transfer (9.0%), and neochordae placement (7.4%), with no or trivial residual MR in over 97% of patients. In
patients having mitral valve replacement, a bioprosthesis was placed in 101 patients (42.6%) and a mechanical
valve in 136 (57.4%). Concomitant procedures included atrial fibrillation ablation (22.5%), tricuspid valve sur-
gery (5.4%), and atrial septal defect closure (9.4%). Nineteen patients (1.6%) experienced intraoperative conver-
sion to sternotomy. Twenty-two patients (1.9%) had a reoperation at a mean of 732  1014 days. Independent
predictors of in-hospital mortality included New York Heart Association class III/IV (odds ratio 3.62), diabetes
(odds ratio 2.81), bypass time>180minutes (odds ratio 2.63), preoperative atrial fibrillation (odds ratio 2.53), and
age>70 years (odds ratio 2.29). Prior cardiac surgery was not a significant predictor of mortality.
Conclusions: Video-assisted mitral valve surgery is safe with high rates of repair, low morbidity, and excellent
outcomes. Reoperation after previous median sternotomy is not an independent predictor of mortality with this
approach. Operative risk is increased if surgery is delayed until the onset of atrial fibrillation.Because of excellent clinical results, minimally invasive
mitral valve surgery (MIMVS) has evolved since the mid-
1990s and has become the preferred method of mitral valve
repair (MVP) and mitral valve replacement (MVR) at certain
specialized centers worldwide. MIMVS refers to a collection
of new techniques and operation-specific technologies, such
as modified perfusion methods and visualization techniques
that are directed toward minimizing surgical trauma. The be-
lief that this approach leads to less pain, shorter hospital
stays, faster return to normal activities, superior cosmesis,
and potential cost savings has driven this development.1,2
However, some surgeons still express concern that restricted
exposure, limited operating space, and longer instruments
may lead to inferior results both in ability to repair the valve
and long-term outcomes.3
Since 1996, surgeons at East Carolina University and the
University of Pennsylvania have had a large experience with
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minithoracotomy. The aim of this study was to review our
collective early results and to examine the safety, efficacy,
and early outcomes of MIMVS.
METHODS
Patients
We prospectively collected pre-, intra-, and postoperative data on all pa-
tients who had video-assisted mitral valve surgery at East Carolina Univer-
sity between May 1996 and April 2008 and the University of Pennsylvania
between November 1998 and October 2007. During this period, all patients
referred with mitral valvular disease were considered for video-assisted
mitral valve surgery. Absolute contraindications to this approach included
severe peripheral vascular disease, a history of a prior right-sided thoracot-
omy/irradiation, concomitant coronary artery disease requiring surgical
revascularization, or concomitant aortic valvular disease requiring replace-
ment. As this was our standard approach, Institutional Review Board
approval was not needed, but standard informed consent regarding surgical
approach and expected outcomes was obtained by either the operating sur-
geon or team. Patients having robotic mitral valve surgery using the da
Vinci system (Intuitive Surgical Inc,Mountain View, Calif) were excluded
from this analysis.
Surgical Technique
Our surgical approach has been described previously4,5 and is summa-
rized here. Each operation was performed through a 4-cm working incision
made in the right infrathoracic groove and carried through the fourth inter-
costal space. Rib spreading was limited by using small thoracic and soft tis-
sue retractors. Each patient had double-lumen endotracheal intubationardiovascular Surgery c Volume 137, Number 6 1481
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DAbbreviations and Acronyms
AF ¼ atrial fibrillation
CPB ¼ cardiopulmonary bypass
EABO ¼ endoaortic balloon occlusion
HF ¼ hypothermic fibrillation
IQR ¼ interquartile range
MIMVS ¼ minimally invasive mitral valve surgery
MVP ¼ mitral valve repair
MVR ¼ mitral valve replacement
OR ¼ odds ratio
TTC ¼ transthoracic clamping
followed by a transesophageal echocardiography study. To minimize intra-
cardiac air retention, the pleural cavity was flooded continuously with CO2.
Vacuum-assisted femoral–femoral cardiopulmonary bypass (CPB) was
used with upper-body venous return augmented through a 15F to 17F right
internal jugular cannula positioned in the superior vena cava. For primary
procedures, aortic occlusion was accomplished by either transthoracic
clamping (TTC) or endoaortic balloon occlusion (EABO), according to sur-
geon preference. For reoperative cases, either hypothermic fibrillation (HF)
or EABO was used. Hypothermic (28C) perfusion and cold (4C–6C) an-
tegrade cardioplegic solution, administered at 15- to 20-minute intervals,
were used for systemic and myocardial protection. When necessary, retro-
grade cardioplegic solution was administered through a transjugular or
transthoracic coronary sinus catheter. Long-shafted instruments were used
to perform each operation (Geister, Plymouth, Mass).
Operative visualization was through a 5-mm endoscope, passed through
an anterior axillary line fourth intercostal space trocar. A left atriotomy
(Waterston’s interatrial groove) wasmade, andMVPs were done using stan-
dard Carpentier techniques. Posterior, anterior, and bileaflet prolapsing
valves were repaired in this series. MVR was performed with interrupted
pledgetted 2-0 Ticron (Tyco Healthcare, Mansfield, Mass) mattress sutures
using both biologic and mechanical valves. Cardiac deairing was performed
by flushing the left atrium across the atrial suture line as well as aortic root
venting. Echocardiography ensured intracardiac air removal andwas used to
monitor valve and ventricular function.
Statistical Analysis
Descriptive statistics were reported using means  standard devia-
tions, medians  interquartile ranges (IQRs), and proportions. Compari-
sons of data between groups were carried out using either a 2-sided t test
or the Kruskal-Wallis test for continuous data and c2 or Fisher exact test
for categorical data. A nonparsimonious, multivariate logistic regression
model was constructed on the basis of pre- and intraoperative variables
to determine predictors of in-hospital mortality with the odds ratio
(OR) of each predictor serving to quantify its relative effect on mortality.
A C-statistic for the model was generated to assess the ability to discrim-
inate between patients with the adverse outcome of interest and those
without any. All analyses were performed using SAS version 9.1.3
(SAS Institute, Cary, NC).
RESULTS
A total of 1178 patients had a minimally invasive mitral
valve procedure (University of Pennsylvania, 634; East
Carolina University, 544). MVP was performed in 941
patients (79.9%) and MVR in 237 patients (20.1%).
Preoperative patient characteristics and echocardiographic
data are shown in Table 1. Patients having MVR had1482 The Journal of Thoracic and Cardiovascular Sa higher risk profile compared with patients having
MVP, with a greater proportion having mitral stenotic
or mixed disease.
Mean aortic occlusion and CPB times were 99.8  37.6
minutes and 142.1  47.1 minutes for MVP procedures
and 115.3  49.7 minutes and 162.1  63.4 minutes for
MVR patients, respectively (Table 2). Concomitant proce-
dures were performed in 390 patients (33.1%) and included
atrial fibrillation (AF) ablation in 265 patients (22.5%), tri-
cuspid valve surgery in 64 patients (5.4%), patent foramen
ovale/atrial septal defect closure in 111 patients (9.4%),
and oversewing of the left atrial appendage in 114 patients
(9.7%).
The transthoracic clamp was used in 573 patients
(48.7%), EABO in 479 patients (40.7%), HF in 120
(10.1%), and TTC þ HF in 6 (0.5%). Compared with
TTC, prior cardiac surgery was more common and operative
times were longer with EABO but the rate of valve repair
was similar (Table 3). The incidence of stroke with EABO
was 2.7% versus 1.2% with TTC (P ¼ .08). There were 7
aortic dissections (1.5%) with the endoballoon (type A,
n ¼ 4; type B, n ¼ 3) and 2 (0.4%) with the transthoracic
clamp (type A, n ¼ 2; P ¼ .09). All patients with a type B
dissection survived without neurologic deficit, whereas 2
of those with type A dissection died (mortality 33%) and
1 further patient had a stroke. There was a significantly
higher rate of conversion to sternotomy and longer hospital
stay with EABO although no significant difference in
mortality.
Among patients having an MVP, repair techniques in-
cluded a ring annuloplasty in 924 patients (98.2%) with
a median ring size of 30 mm (IQR 28–34 mm), Carpent-
ier-type leaflet resection in 383 patients (40.7%), sliding
plasty in 198 patients (21.0%), chordal transfer in 85 pa-
tients (9.0%), and polytetrafluoroethylene neochordae
placement in 70 patients (7.4%; Table 4). The intraoperative
transesophageal echocardiogram demonstrated that 97.1%
of patients having MVP for MR left the operating room
with no more than trivial residual MR (Table 5). In patients
having MVR, a bioprosthesis was placed in 101 (42.6%)
and a mechanical valve in 136 (57.4%).
Nineteen patients (1.6%) had intraoperative conversion
to sternotomy (MVR 6, MVP 13), the reasons being: type
A aortic dissection (n ¼ 6), atrioventricular groove disrup-
tion (n ¼ 6), circumflex artery injury (n ¼ 2), severe mitral
annular calcification (n ¼ 1), contralateral tension pneumo-
thorax (n¼ 1), aortoinnominate junction injury (n¼ 1), dif-
ficult aortic occlusion (n ¼ 1), and other (n ¼ 1).
Postoperative and Midterm Outcomes
Overall operative mortalities for MVP and MVR were
2.1% and 4.6%, respectively. Mortalities for isolated
MVP and MVR were 0.8% and 3.9% and for isolated pri-
mary MVP and MVR were 0.2% and 3.6%, respectively.urgery c June 2009
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Variable Overall (n ¼ 1178) Repair (n ¼ 941) Replacement (n ¼ 237) P value
Age, y (mean  SD) 61.1  13.9 60.8  13.9 62.6  13.7 .06
Female sex (%) 51.0 47.7 64.1 <.0001
Previous cardiac surgery 18.8 13.2 40.9 <.0001
Diabetes (%) 11.5 11.1 13.5 .51
Hypertension (%) 44.8 43.8 49.0 .15
Pulmonary hypertension (%) 35.7 31.1 54.0 <.0001
Preoperative atrial fibrillation 36.5 35.5 40.5 .15
Congestive heart failure (%) 60.5 55.9 78.9 <.0001
NYHA class III/IV (%) 43.9 38.6 65.0 <.0001
Echocardiographic findings
Mitral regurgitation
None (%) 1.4 0.3 5.5
Trivial (%) 0.4 0.2 1.3
Mild (%) 2.4 1.7 5.1
Moderate (%) 7.8 6.8 11.8
Severe (%) 88.0 91.0 76.4 <.0001
Mitral stenosis (%) 9.9 2.2 40.1 <.0001
Tricuspid insufficiency
None (%) 58.8 60.2 53.6
Trivial (%) 2.8 3.2 1.3
Mild (%) 20.5 20.9 19.0
Moderate (%) 12.7 11.4 17.7
Severe (%) 5.2 4.4 8.4 .003
Ejection fraction (mean) 52.8  12.1 52.4  12.1 54.1  11.9 .05
Ejection fraction<50% (%) 26.7 28.0 21.9 .06
NYHA, New York Heart Association functional class; SD, standard deviation.Reoperation for bleeding was required in 63 patients
(5.4%), with the same video-assisted approach used in all
patients without the need for conversion to sternotomy. Post-
operative strokes were observed in 23 patients (2.0%). Me-
dian hospital stay was 6 days (IQR 5–8 days). Other
complications are shown in Table 6. Twenty-two patients
(1.9%) had a reoperation at a mean of 732  1014 days
as the result of either recurrent severe MR (n¼ 13), endocar-
ditis (n ¼ 3), recurrent severe MS (n ¼ 2), valve dehiscence
(n ¼ 2), systolic anterior motion (n ¼ 1), or hemolysis
(n ¼ 1).
Multivariate logistic regression modeling revealed that
New York Heart Association functional class III/IV, diabe-
tes, CPB time>180 minutes, preoperative AF, and age>70
years were independent predictors of mortality, whereas pre-
vious cardiac surgery was not (Table 7). The C-statistic of
the model was 0.86.
DISCUSSION
This series comprises our total experience, including our
learning curve, of minimally invasive video-assisted mitral
valve surgery from May 1996 until May 2008. The in-hos-
pital mortalities of 0.8% and 3.9% for isolated MVP and
MVR, respectively, are lower than the reported operative
mortality rates in the Society of Thoracic Surgeons Fall
2007 report (1.6% and 6.1%, respectively).6 The mortalityThe Journal of Thoracic and Cfigures in our series are also concordant with other reports of
the same technique ranging from 0.4% to 2.4% for MVP
and from 2.5% to 5.8% for MVR.7-10
Critics of MIMVS suggest that MVP may be performed
less frequently and that the repair may be less durable than
that obtained through a sternotomy. The greater degree of
difficulty presented by limited operating space, long instru-
ments, and video assistance are cited as reasons for this opin-
ion.7 Overall, 79.9% of our patients had a repair; however,
of those having a repair for MR, our repair rate was 86.6%.
This is similar to the series reported by Seeburger and col-
leagues7 (1536 patients, 87.2%), Aybek and associates11
(241 patients, 83%), Casselman and coworkers8 (306 pa-
tients, 74%), and Grossi’s group9 (561 patients, 66.8%), us-
ing the right minithoracotomy approach; and Mihaljevic and
colleagues12 (474 patients, 88%), using the lower hemister-
notomy; or Suri and associates13 (1411 patients, 83%), us-
ing a median sternotomy. This clearly demonstrates that
this technique is reproducible with repair rates comparable
to both conventional surgery and other minimally invasive
approaches with over 97% of patients leaving the operating
room with no more than trivial residual regurgitation. Thus,
the early results of repair are clearly not compromised by this
less invasive approach. In terms of durability, a reoperative
rate of 1.9% at just over 2 years is consistent with published
sternotomy repair data.13ardiovascular Surgery c Volume 137, Number 6 1483
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Variable Overall (n ¼ 1178) Repair (n ¼ 941) Replacement (n ¼ 237) P value
Valve replacement type
Bioprosthetic (%) — — 42.6
Mechanical (%) — — 57.4
CPB time, min (mean  SD) 146.1  51.4 142.1  47.1 162.1  63.4 <.0001
CPB time>180 min (%) 18.7 16.6 27.0 .0002
Aortic occlusion time, min (mean  SD) 104.6  40.3 99.8  37.6 115.3  49.7 <.0001
Hypothermic fibrillation, min (mean  SD) 101.4  44.1 91.7  36.1 118.8  51.9 .004
Additional procedures (%)
Tricuspid valve repair/replacement 5.4 5.4 5.5 .97
ASD/PFO closure 9.4 11.1 3.0 .0001
Maze/ablation 22.5 24.9 13.1 .0001
Left atrial appendage exclusion 9.7 10.4 6.8 .09
Myocardial protection technique (%)
Transthoracic clamp 48.7 48.7 48.5
Endoaortic balloon occlusion 40.7 43.0 31.2
Hypothermic fibrillation 10.1 8.0 19.8
Hypothermic fibrillationþclamp 0.5 0.3 0.4 <.0001
Conversion to sternotomy (%) 1.6 1.4 2.5 .21
ASD, Atrial septal defect; CPB, cardiopulmonary bypass; PFO, patent foramen ovale; SD, standard deviation.The increased operative risk associated with advanced age
is ubiquitous in surgical articles14; however, the importance
of a reoperative sternotomy has been deemphasized.15-17 In
a multivariate logistic regression model of 409,904 valve
procedures performed between 1994 and 2003 and cata-
loged in the Society of Thoracic Surgeons database, the third
most important preoperative variable influencing operative
mortality was a reoperation (OR 1.61, P<.001).18 However,
our data suggest that a right minithoracotomy approach after
previous median sternotomy is not an independent predictor
of mortality (OR 1.13, P¼ .77). This important finding sug-
TABLE 3. Comparison of endoaortic balloonocclusion to transthoracic
clamping
Variable EABO TTC P value
n 479 573
Previous cardiac
surgery (%)
15.0 6.6 <.0001
CPB time (min) 149.0  53.2 142.2  48.8 .03
Aortic occlusion time
(min)
112.0  43.8 99.4  35.8 <.0001
Mitral valve repair rate
(%)
84.6 79.9 .051
Permanent stroke 2.7 1.2 .08
Reoperation for bleeding 6.7 4.7 .17
Aortic dissection 1.5 0.4 .09
Conversion to sternotomy 2.9 0.9 .01
Hospital length of stay
(days), median (IQR)
7 (5–8) 5 (4–7) <.001
Mortality (%) 1.5 2.3 .34
CPB, Cardiopulmonary bypass; EABO, endoaortic balloon occlusion; IQR, interquar-
tile range; TTC, transthoracic clamping.1484 The Journal of Thoracic and Cardiovascular Surgests that, in terms of early outcomes, this should be the
technique of choice for reoperative mitral valve surgery in
patients who do not need a concomitant aortic valve replace-
ment or coronary revascularization. This is concordant with
data demonstrating equivalent or lower mortality rates and
less morbidity for a right minithoracotomy approach versus
a reoperative sternotomy.19-21 However, data on mid- and
long-term outcomes are needed.
Patients with AF frequently present with more severe
symptoms with increased cardiac morbidity in the form of
a prior myocardial infarction, cardiomegaly, tricuspid valve
regurgitation, and/or pulmonary hypertension. Prior nonsur-
gical series have identified AF as a marker of severe cardiac
disease and a specific risk factor for decreased long-term
survival.22,23 Moreover, numerous surgical series have
documented poorer long-term outcomes in patients with
AF having mitral valve,24-27 coronary,28 or aortic valve sur-
gery.29 The influence on both short-term outcomes and op-
erative mortality has hitherto been less clear. Both Lim
and associates25 and Chua and colleagues30 demonstrated
no difference in operative mortality for patients with AF
TABLE 4. Details of mitral valve repair technique
Valve repair technique n % of 941
Annuloplasty 924 98.2
Median ring size (IQR), mm 30 (28–34) —
Leaflet resection 383 40.7
Sliding plasty 198 21.0
Chordal shortening 9 1.0
Chordal transfer 85 9.0
Polytetrafluoroethylene chordal placement 70 7.4
IQR, Interquartile range.gery c June 2009
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more recently published study of 2821 Mayo Clinic patients
documents higher operative mortality for AF patients,24
data that are supported by Alexiou and colleagues.26 How-
ever, differences in baseline characteristics between patients
with/without AF may have confounded these results. Our
data, in a multivariate logistic regression model, clearly dem-
onstrate that preoperative AF is an independent predictor of
operative mortality following MIMVS. This strengthens the
argument for early operative intervention in mitral valve
disease prior to the development of AF.
Aortic dissection associated with a minimally invasive ap-
proach may occur either at the site of aortic occlusion, be it
endoaortic or transthoracic, or from the femoral cannulation
site through retrograde malperfusion. Although the inci-
dence of dissection and strokes was higher with EABO in
our series, these differences were not statistically significant.
In the first Port Access International Registry (PAIR) report,
the incidence of aortic dissection was 1.3% in the first half of
the study compared with 0.2% in the second half, a differ-
ence attributable to experience, better techniques, and im-
proved technology particularly balloon design.10 Grossi
and colleagues,9 Casselman and associates,8 and Onnasch
and coworkers31 reported dissection rates of 0.3% (2/714),
0.7% (2/306), and 1.4% (3/209) with EABO, and the latter
also reported a significantly higher incidence of neurologic
complications with EABO compared with the transthoracic
clamp. These concerns led the authors to abandon EABO for
TABLE 5. Results of pre- and postoperative transesophageal
echocardiogram for patients having mitral valve repair for mitral
regurgitation
Prerepair Postrepair
Mitral regurgitation n % n %
None 0 0 680 75.0
Trivial 0 0 202 22.2
Mild 0 0 24 2.6
Moderate 62 6.8 2 0.2
Severe 846 93.2 0 0.0primary mitral valve procedures.31 Although, operative
times are longer with EABO, a finding that has been mir-
rored by other smaller studies,32,33 this does not have a neg-
ative influence on the valve repair rate. These studies also
demonstrated fewer technical difficulties and complications,
less blood loss, and lower costs using the transthoracic
clamp. Our data also demonstrate a longer postoperative
stay with EABO. However, as EABO is predominantly
used at 1 center, differing institutional practices may be
a confounding variable.
Aortic dissection and atrioventricular groove disruption
were the commonest reasons for conversion to sternotomy
in our series, which occurred in 1.6% of patients. Conver-
sion to median sternotomy generally occurs infrequently
during the right minithoracotomy approach and others
have reported this in 0.3%,7 1.1%,9 and 2.0%8 of patients.
For the upper-hemisternotomy approach, this complication
has been reported in 2.4% to 2.6% of patients, mostly due
to bleeding, refractory arrhythmias, or ventricular dysfunc-
tion, whereas for the lower-hemisternotomy approach, this
occurred in 4.0% of patients, most commonly due to poor
exposure.34,35
A reduction in postoperative hemorrhage, transfusion
requirements, and need for reexploration for bleeding
have been suggested as potential advantages of minimally
invasive valve surgery due to a reduction in surgical
trauma. This benefit is important given the significant
morbidity and mortality associated with transfusions and
reexploration.36 Our data show that 45.5% of patients
needed transfusion of blood or blood products (MVP
40.7%, MVR 64.6%). Reexploration for bleeding oc-
curred in 5.4% of patients; other similar studies have re-
ported this in 4.9%,9 5.1%,7 and 8.5% of patients.8 The
STS database between 1994 and 2003 reported this in
5.5% of all valvar procedures.18 A recently reported
meta-analysis of MIMVS did, however, suggest a signifi-
cantly reduced need for reoperation for bleeding compared
with median sternotomy.37 In the majority of cases, the
source of bleeding was from the chest wall and, in all
cases, reexploration was accomplished safely through theTABLE 6. Postoperative outcomes and complications
Variable Overall (n ¼ 1178) Repair (n ¼ 941) Replacement (n ¼ 237) P value
Ventilator time (h), median (IQR) 7.6 (4.0–12.0) 7.0 (4.0–11.0) 10.0 (7.0–18.0) <.0001
New-onset atrial fibrillation (%) 26.7 25.4 32.6 .08
Permanent stroke (%) 2.0 1.9 2.1 .84
Transfusion (%) 45.5 40.7 64.6 <.0001
Reoperation for bleeding (%) 5.4 5.1 6.8 .32
Infection (%) 0.6 0.5 0.8 .58
Aortic dissection (%) 0.8 0.6 1.3 .32
Hospital length of stay (d), median (IQR) 6 (5–8) 6 (4–7) 7 (5–10) <.0001
Mortality (%) 2.6 2.1 4.6 .03
IQR, Interquartile range.
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conversion to sternotomy. From a technical aspect, we
have found a 30 videoscope and dental mirror useful ad-
juncts for assessing chest wall hemostasis.
In summary, video-assisted MIMVS is safe and associated
with a high rate of repair, lowperioperativemorbidity, and ex-
cellent early echocardiographic results.When compared with
the transthoracic clamp, the EABO technique had a higher in-
cidence of aortic dissection and strokes, although these differ-
ences did not reach statistical significance. Reoperative
surgery, after a previousmedian sternotomy, was not an inde-
pendent predictor for mortality, suggesting that the minithor-
acotomy approach may be superior to sternotomy in terms of
early outcomes. Preoperative AF was an independent predic-
tor of mortality, demonstrating that operative risk is increased
if surgery is delayed until the onset of AF.
We acknowledge the enormous contributions of Jeanne Fox and
Linda Kindell in data collection.
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